[Federal Register Volume 84, Number 38 (Tuesday, February 26, 2019)]
[Notices]
[Page 6128]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-03236]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-05-2019]


Foreign-Trade Zone (FTZ) 93--Raleigh/Durham, North Carolina, 
Notification of Proposed Production Activity, GlaxoSmithKline, PLC 
(Pharmaceutical Products), Zebulon, North Carolina

    The Triangle J Council of Governments, grantee of FTZ 93, submitted 
a notification of proposed production activity to the FTZ Board on 
behalf of GlaxoSmithKline, PLC (GlaxoSmithKline), located in Zebulon, 
North Carolina. The notification conforming to the requirements of the 
regulations of the FTZ Board (15 CFR 400.22) was received on February 
13, 2019.
    GlaxoSmithKline already has authority to produce certain 
pharmaceutical products within Site 6 of FTZ 93. The current request 
would add finished products and a foreign-status material/component to 
the scope of authority. Pursuant to 15 CFR 400.14(b), additional FTZ 
authority would be limited to the specific foreign-status material/
component (dolutegravir sodium) and specific finished products 
described in the submitted notification (as described below) and 
subsequently authorized by the FTZ Board.
    Production under FTZ procedures could exempt GlaxoSmithKline from 
customs duty payments on the foreign-status material/component used in 
export production. On its domestic sales, for foreign-status 
dolutegravir sodium (duty rate, 6.5%) and foreign-status components in 
the existing scope of authority, GlaxoSmithKline would be able to 
choose the duty-free rate during customs entry procedures that applies 
to: Dolutegravir sodium/rilpivirine HCl; Juluca tablets[supreg] (anti-
viral); dolutegravir sodium tablets (anti-viral); Tivicay 
tablets[supreg] (anti-viral); abacavir sulfate/dolutegravir sodium/
lamivudine tablets (anti-viral); Triumeq tablets[supreg] (anti-viral); 
dolutegravir/lamivudine tablets (anti-viral); Dovato tablets[supreg] 
(anti-viral); umeclidinium bromide/vilanterol trifenatate ellipta 
(respiratory inhaler); Anoro Ellipta[supreg] (respiratory inhaler); 
umeclidinium bromide ellipta (respiratory inhaler); Incruse 
Ellipta[supreg] (respiratory inhaler); fluticasone furoate/umeclidinium 
bromide/vilanterol trifenatate ellipta (respiratory inhaler); and, 
Trelegy Ellipta[supreg] (respiratory inhaler). GlaxoSmithKline would be 
able to avoid duty on foreign-status components which become scrap/
waste. Customs duties also could possibly be deferred or reduced on 
foreign-status production equipment.
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary at the address 
below. The closing period for their receipt is April 8, 2019.
    A copy of the notification will be available for public inspection 
at the Office of the Executive Secretary, Foreign-Trade Zones Board, 
Room 21013, U.S. Department of Commerce, 1401 Constitution Avenue NW, 
Washington, DC 20230-0002, and in the ``Reading Room'' section of the 
Board's website, which is accessible via www.trade.gov/ftz.
    For further information, contact Diane Finver at 
[email protected] or (202) 482-1367.

    Dated: February 19, 2019.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2019-03236 Filed 2-25-19; 8:45 am]
 BILLING CODE 3510-DS-P